Opava 1

This research aims to evaluate the long-term safety and explore the efficacy of astegolimab in adults aged 40 to 90 years with chronic obstructive pulmonary disease COPD. It focuses on participants who have completed a 52-week placebo-controlled treatment period in previous studies GB43311 or GB44332. The study is a phase 3, open-label extension to gather extended safety information on this drug in COPD patients. Participants from the parent studies who qualify will receive subcutaneous injections of astegolimab every two weeks throughout the study until it ends. This open-label extension allows all participants to receive the active drug without placebo comparison. The study continues treatment beyond the initial 52-week period to monitor long-term effects. During the study, participants will be monitored for adverse events up to 12 weeks after their last dose of astegolimab. Researchers will collect safety data to understand the incidence of any side effects. The study involves regular assessments and follow-ups to ensure participant well-being, with the total duration lasting until July 2034.

Researchers are conducting a national, prospective, multicenter, non-interventional pilot project to screen for Hepatitis C virus HCV infection among people who inject drugs PWID in the Czech Republic. The main goal is to prepare, implement, and assess a method for early detection of Hepatitis C and to develop new procedures for integrating this screening into social health care systems. This project aims to help prevent further transmission of the virus by improving early diagnosis and care continuity.

The study focuses on patients with various conditions related to plasma cells, including Monoclonal Gammopathy of Undetermined Significance MGUS, smoldering Multiple Myeloma SMM, Multiple Myeloma MM, and Plasma Cell Leukemia PCL. It is an observational, non-interventional, multicenter research project aimed at collecting, storing, and analyzing biological samples from these patients. The purpose is to create an international infrastructure for gathering consistent clinical data and biological samples at different stages of disease and treatment. Participants provide biological samples such as bone marrow aspirate, bone marrow biopsy, extramedullary disease EMD biopsy, peripheral blood, and serum at multiple timepoints. These include baseline, pre-maintenance or after one year of therapy depending on transplant eligibility, during maintenance therapy if part of standard care, and at first or later progression of disease. The study collects and stores these samples over a long period to support future research. Participants will undergo sample collections at scheduled times during their disease course and treatment phases. Researchers will monitor and analyze the stored biological samples and clinical data to support a biobank lasting up to 30 years. The study does not involve any experimental treatments but focuses on gathering data and samples to better understand the conditions. Participation requires written informed consent and compliance with the protocols follow-up schedule.

This research aims to evaluate the use of the Sirius Pintuition magnetic seed device for locating non-palpable malignant breast tumors and pathological lymph nodes in patients undergoing breast cancer surgery. The study is conducted as a prospective pilot study in the Czech Republic, focusing on improving the precision of tumor localization during surgery. This observational study involves patients with breast cancer confirmed by biopsy who require surgical treatment. Participants will have their non-palpable breast cancer or pathological lymph nodes localized using the magnetic seed Sirius Pintuition device. This device is placed to assist surgeons in accurately identifying the tumor or affected lymph nodes during surgery. The study does not involve any comparison groups or placebo treatments, as it is observational and device-focused. Throughout the study, participants will be monitored and evaluated for up to one year to assess hypotheses related to the effectiveness of the device in localization. The primary and secondary outcome measures will be reviewed after one year. Patient involvement includes undergoing the localization procedure with the device and subsequent breast cancer surgery, with follow-up to gather data on the localization process and surgical outcomes.